<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="11266"><DrugName>pilocarpine (ophthalmic formulation, DuraSite), InSite</DrugName><DrugNamesKey><Name id="42776675">PilaSite</Name><Name id="42814622">pilocarpine</Name><Name id="42759386">pilocarpine hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>pilocarpine hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>(+)-pilocarpine</Value></Name><Name><Value>PilaSite</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>pilocarpine (ophthalmic formulation, DuraSite), InSite</Value></Name><Name><Value>pilocarpine</Value><Types><Type>BANN</Type></Types></Name><Name><Value>54-71-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>92-13-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17230">InSite Vision Inc</CompanyOriginator><CompaniesSecondary><Company id="14410">Bausch &amp; Lomb Inc</Company><Company id="15449">Novartis Ophthalmics Inc</Company><Company id="17230">InSite Vision Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14410" type="Company"><TargetEntity id="4295903550" type="organizationId">Bausch &amp; Lomb Inc</TargetEntity></SourceEntity><SourceEntity id="15449" type="Company"><TargetEntity id="5000356602" type="organizationId">Novartis Ophthalmics Inc</TargetEntity></SourceEntity><SourceEntity id="17230" type="Company"><TargetEntity id="5000143831" type="organizationId">Insite Vision Ltd</TargetEntity></SourceEntity><SourceEntity id="134" type="ciIndication"><TargetEntity id="H40" type="ICD10"/><TargetEntity id="365" type="ICD9"/><TargetEntity id="10018304" type="MEDDRA"/><TargetEntity id="D005901" type="MeSH"/><TargetEntity id="-1306155249" type="omicsDisease"/><TargetEntity id="777" type="siCondition"/></SourceEntity><SourceEntity id="258" type="Action"><TargetEntity id="9" type="Mechanism">Muscarinic Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="134">Glaucoma</Indication></IndicationsSecondary><ActionsPrimary><Action id="258">Muscarinic receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="15137">Topical antiglaucoma agent</Action></ActionsSecondary><Technologies><Technology id="620">Ophthalmic formulation</Technology><Technology id="589">Sustained release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>S1E2</Code><Name>Miotics and antiglaucoma preparations, topical</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-27T10:28:47.000Z</LastModificationDate><ChangeDateLast>2017-11-27T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;InSite was developing an eyedrop formulation of pilocarpine (PilaSite) for the treatment of glaucoma, using its patented DuraSite delivery system. The development has been discontinued after it reached phase III trials [&lt;ulink linkID="352381" linkType="reference"&gt;352381&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase III trial showed that twice daily dosing of glaucoma patients with PilaSite was as effective as conventional pilocarpine administered four times a day [&lt;ulink linkID="177060" linkType="reference"&gt;177060&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The trial was completed during the course of 1995, and the company had scheduled an NDA filing for this sustained release formulation for 1996 [&lt;ulink linkID="195065" linkType="reference"&gt;195065&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15449">Novartis Ophthalmics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="134">Glaucoma</Indication><StatusDate>1996-06-07T00:00:00.000Z</StatusDate><Source id="209443" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17230">InSite Vision Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="134">Glaucoma</Indication><StatusDate>1998-07-01T00:00:00.000Z</StatusDate><Source id="352381" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14410">Bausch &amp; Lomb Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="134">Glaucoma</Indication><StatusDate>1996-07-31T00:00:00.000Z</StatusDate><Source id="352381" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14410">Bausch &amp; Lomb Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="134">Glaucoma</Indication><StatusDate>1996-07-24T00:00:00.000Z</StatusDate><Source id="214156" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17230">InSite Vision Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="134">Glaucoma</Indication><StatusDate>1995-11-07T17:12:08.000Z</StatusDate><Source id="177060" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01362"><Name>Muscarinic receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17058">Bausch Health Companies Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27561">Sun Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC[C@H]1[C@H](COC1=O)Cc2cncn2C</Smiles><Smiles>CC[C@H]1[C@H](COC1=O)Cc2cncn2C.Cl</Smiles></StructureSmiles><Deals><Deal id="123109" title="Bausch &amp; Lomb and InSite Vision to enter manufacture, development and marketing agreement"/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>